Kim NH, et al. – In this study, researchers investigated the long-term efficacy and safety of CT-P13 therapy for inflammatory bowel disease (IBD). Between July 2012 and December 2017, they assessed 368 patients with IBD (227 with Crohn's disease [CD] and 141 with ulcerative colitis [UC]) who received CT-P13. At years 1, 3, and 5, cumulative retention rates were 86.1%, 68.5%, 58.7%, and 69.7%, 46.0%, and 26.7%, respectively, in patients with anti-tumor necrosis factor (TNF)-naïve CD and UC. According to outcomes, significant improvements in disease activity scores were accompanied by marked decreases in inflammatory marker levels, and no unforeseen adverse events including death or malignancy occurred during the period of study. In all, long-term CT-P13 treatment was found to be effective in inducing and maintaining improvement in disease, and was well-tolerated in this cohort of IBD patients. The investigators suggested that CT-P13 can be a promising option for IBD treatment.